Drug Discovery & Development | Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartis pharmabiz.com CTI is currently accruing patients into a phase III trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the United States. Opaxio (paclitaxel ... Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 - Update Cell Therapeutics Inc : Cell Therapeutics Announces 2014 Outlook and Recent ... |
